. 2022 Sep 6;16:100454. doi: 10.1016/j.abrep.2022.100454

Table 3.

Change over time in lifetime and 12-month prevalence of tryptamine use, NSDUH.

	Lifetime				12-month
	Prevalence % (SE)^a		Prevalence difference % (95 % CI)^a^,^b	Trend differences by age group % (95 % CI)^c	Prevalence % (SE)^a		Prevalence difference % (95 % CI)^a^,^b	Trend differences by age group % (95 % CI)^c
	Start year	End year			Start year	End year
	*2006*	*2014*			*2006*	*2014*
Whole sample	0.23 (0.01)	0.79 (0.04)	0.55 (0.45, 0.65)		0.04 (0.00)	0.18 (0.02)	0.14 (0.10, 0.18)
Ages 12–17	0.16 (0.03)	0.33 (0.05)	0.17 (0.07, 0.27)	−0.23 (−0.37, −0.09)	0.10 (0.03)	0.23 (0.07)	0.13 (0.03, 0.23)	0.07 (−0.05, 0.19)
Ages 18–25	0.73 (0.04)	2.58 (0.12)	1.84 (1.55, 2.13)	1.45 (1.14, 1.76)	0.17 (0.02)	0.81 (0.07)	0.64 (0.48, 0.80)	0.57 (0.41, 0.73)
Ages ≥ 26	0.16 (0.02)	0.56 (0.05)	0.39 (0.29, 0.49)	Reference	0.01 (0.00)	0.08 (0.02)	0.07 (0.03, 0.11)	Reference
	*2015*	*2019*			*2015*	*2019*
Whole sample	0.78 (0.04)	1.22 (0.05)	0.44 (0.28, 0.60)		0.14 (0.01)	0.14 (0.01)	0.00 (0.00, 0.00)
Ages 12–17	0.27 (0.06)	0.33 (0.08)	0.06 (−0.16, 0.28)	−0.51 (−0.75, −0.27)	0.22 (0.06)	0.23 (0.12)	0.01 (−0.19, 0.21)	−0.06 (−0.26, 0.14)
Ages 18–25	2.22 (0.10)	2.13 (0.11)	−0.09 (−0.42, 0.24)	−0.66 (−0.86, −0.46)	0.40 (0.05)	0.58 (0.08)	0.18 (−0.04, 0.40)	0.10 (−0.14, 0.34)
Ages ≥ 26	0.61 (0.03)	1.17 (0.06)	0.56 (0.42, 0.70)	Reference	0.05 (0.01)	0.12 (0.02)	0.07 (0.01, 0.13)	Reference

Note: Significant trends (p-values < 0.05) are shown in bold. 2002–2019 (N = 1,006,051); 2002–2014 (N = 723,283); 2006–2014 (N = 502,467); 2015–2019 (N = 241,708).

Adjusted for gender, age, race/ethnicity, educational level, and family income.

Calculated as difference between the predicted prevalence in the end and start year.

Estimated as the difference between the prevalence difference for each group (12–17 and 18–25 versus the ≥ 26 reference group).